PE20140018A1 - Una composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodica - Google Patents
Una composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodicaInfo
- Publication number
- PE20140018A1 PE20140018A1 PE2013000910A PE2013000910A PE20140018A1 PE 20140018 A1 PE20140018 A1 PE 20140018A1 PE 2013000910 A PE2013000910 A PE 2013000910A PE 2013000910 A PE2013000910 A PE 2013000910A PE 20140018 A1 PE20140018 A1 PE 20140018A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- ethylbutyl
- carbonyl
- phenyl
- amino
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- -1 [[1- (2-ETHYLBUTYL) CYCLOHEXYL] -CARBONYL] AMINO Chemical class 0.000 title abstract 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052708 sodium Inorganic materials 0.000 title abstract 2
- 239000011734 sodium Substances 0.000 title abstract 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 abstract 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE LA PROTEINA DE TRANSFERENCIA DEL ESTER DE COLESTERILO (CETP) TAL COMO 2-METILPROPANOTIOATO DE S-[2-([[1-(2-ETILBUTIL)-CICLOHEXIL]-CARBONIL]AMINO)FENILO] EN UNA CANTIDAD DE 10 A 69% EN PESO DE LA COMPOSICION; B) CROSCARMELOSA SODICA EN UNA CANTIDAD DE 1 A 10% EN PESO DE LA COMPOSICION; Y C) EXCIPIENTES POLIMERICOS HIGROSCOPICOS TALES COMO HIDROXIPROPILMETILCELULOSA, CELULOSA MICROCRISTALINA, POLIVINILPIRROLIDONA RETICULADA MICRONIZADA, ENTRE OTROS, EN UNA CANTIDAD DE 34 A 44% EN PESO DE LA COMPOSICION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ATEROSCLEROSIS, HIPERCOLESTEROLEMIA, ANGINA, APOPLEJIA, INFARTO DE MIOCARDIO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10190045 | 2010-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140018A1 true PE20140018A1 (es) | 2014-01-31 |
Family
ID=43759428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000910A PE20140018A1 (es) | 2010-11-04 | 2011-10-31 | Una composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodica |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9107836B2 (es) |
| EP (1) | EP2635263B1 (es) |
| JP (1) | JP5676005B2 (es) |
| KR (1) | KR101579659B1 (es) |
| CN (2) | CN103200935A (es) |
| AR (1) | AR083693A1 (es) |
| BR (1) | BR112013010704B8 (es) |
| CA (1) | CA2815280C (es) |
| CL (1) | CL2013001164A1 (es) |
| CR (1) | CR20130181A (es) |
| EA (1) | EA025649B1 (es) |
| EC (1) | ECSP13012603A (es) |
| ES (1) | ES2553279T3 (es) |
| IL (1) | IL225780B (es) |
| MA (1) | MA34643B1 (es) |
| MX (1) | MX345650B (es) |
| MY (1) | MY164729A (es) |
| NZ (1) | NZ609529A (es) |
| PE (1) | PE20140018A1 (es) |
| PH (1) | PH12013500864A1 (es) |
| SG (1) | SG190025A1 (es) |
| TW (1) | TWI507192B (es) |
| UA (1) | UA110117C2 (es) |
| WO (1) | WO2012059447A1 (es) |
| ZA (1) | ZA201302954B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2395991T1 (sl) | 2009-02-10 | 2013-12-31 | Amarin Pharmaceuticals Ireland Limited | Uporaba etil estra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije |
| EP2978859B1 (en) | 2013-03-27 | 2018-06-27 | F.Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy |
| JP5871984B2 (ja) * | 2013-04-15 | 2016-03-01 | 株式会社三和化学研究所 | オルメサルタンメドキソミルを含有する医薬組成物 |
| EP3082784A1 (en) | 2013-12-19 | 2016-10-26 | F.Hoffmann-La Roche Ag | Cetp modulator for use in the treatment of eye disease |
| RU2703192C2 (ru) | 2014-07-30 | 2019-10-15 | Ф. Хоффманн-Ля Рош Аг | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами |
| CN104434913A (zh) * | 2014-12-20 | 2015-03-25 | 长沙佰顺生物科技有限公司 | 一种安塞曲匹药物组合物及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| US7208465B2 (en) * | 2000-11-03 | 2007-04-24 | The Procter & Gamble Company | Methods and compositions for improved fragrancing of a surface |
| KR20050088190A (ko) * | 2002-12-20 | 2005-09-02 | 화이자 프로덕츠 인코포레이티드 | 콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태 |
| WO2004082675A1 (en) | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate |
| MXPA05009848A (es) * | 2003-03-17 | 2005-12-06 | Japan Tobacco Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo. |
| EP1653926A1 (en) * | 2003-08-04 | 2006-05-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| US20080138428A1 (en) * | 2005-01-28 | 2008-06-12 | Pfizer Inc. | Fast-Disintegrating Microporous Binders |
| US7435849B2 (en) | 2005-10-31 | 2008-10-14 | Hoffmann-La Roche Inc. | Process for the production of acid chlorides |
| EP1935867A1 (en) | 2006-12-20 | 2008-06-25 | F. Hoffmann-La Roche Ag | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid |
| EP2373344B1 (en) * | 2008-12-08 | 2016-03-30 | F. Hoffmann-La Roche AG | Combined drug administration |
| US20110004011A1 (en) | 2009-07-01 | 2011-01-06 | Declan Costello | Novel process |
-
2011
- 2011-10-31 MY MYPI2013700710A patent/MY164729A/en unknown
- 2011-10-31 BR BR112013010704A patent/BR112013010704B8/pt active IP Right Grant
- 2011-10-31 JP JP2013537093A patent/JP5676005B2/ja active Active
- 2011-10-31 EA EA201390622A patent/EA025649B1/ru not_active IP Right Cessation
- 2011-10-31 UA UAA201306203A patent/UA110117C2/uk unknown
- 2011-10-31 CA CA2815280A patent/CA2815280C/en active Active
- 2011-10-31 ES ES11776201.3T patent/ES2553279T3/es active Active
- 2011-10-31 EP EP11776201.3A patent/EP2635263B1/en active Active
- 2011-10-31 PE PE2013000910A patent/PE20140018A1/es not_active Application Discontinuation
- 2011-10-31 WO PCT/EP2011/069087 patent/WO2012059447A1/en not_active Ceased
- 2011-10-31 SG SG2013032123A patent/SG190025A1/en unknown
- 2011-10-31 NZ NZ609529A patent/NZ609529A/en unknown
- 2011-10-31 CN CN2011800532370A patent/CN103200935A/zh active Pending
- 2011-10-31 MX MX2013004584A patent/MX345650B/es active IP Right Grant
- 2011-10-31 KR KR1020137014214A patent/KR101579659B1/ko active Active
- 2011-10-31 CN CN201610309140.6A patent/CN105833283A/zh active Pending
- 2011-10-31 PH PH1/2013/500864A patent/PH12013500864A1/en unknown
- 2011-11-03 TW TW100140194A patent/TWI507192B/zh not_active IP Right Cessation
- 2011-11-03 US US13/288,082 patent/US9107836B2/en active Active
- 2011-11-03 AR ARP110104077A patent/AR083693A1/es unknown
-
2013
- 2013-04-15 IL IL225780A patent/IL225780B/en active IP Right Grant
- 2013-04-23 ZA ZA2013/02954A patent/ZA201302954B/en unknown
- 2013-04-24 CR CR20130181A patent/CR20130181A/es unknown
- 2013-04-29 CL CL2013001164A patent/CL2013001164A1/es unknown
- 2013-05-03 EC ECSP13012603 patent/ECSP13012603A/es unknown
- 2013-05-03 MA MA35868A patent/MA34643B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140018A1 (es) | Una composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodica | |
| PE20140831A1 (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| PE20140849A1 (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida | |
| PE20080519A1 (es) | Derivados de ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-1-il-piridin-3-ilamino)pirimidin-4-iloxi]-piperidina-1-carboxilico y sus composiciones farmaceuticas | |
| UY29575A1 (es) | Formas polimórficas del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino--imino-metil)-fenilamino)-metil)-1-metil-h-bencimidazol-5-carbonil)-piridin-2-il- -amino)-propiónico | |
| PE20130340A1 (es) | (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida como antagonista del receptor de peptido relacionado con el gen de la calcitonina (cgrp) | |
| PE20141056A1 (es) | Metodos para el tratamiento de vhc | |
| PE20130239A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| EA201400553A1 (ru) | Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида | |
| EA201190320A1 (ru) | Гетероциклические сульфонамиды, их применения и фармацевтические композиции | |
| PE20141994A1 (es) | Formulaciones farmaceuticas | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| PE20100083A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| HN2011003072A (es) | Sales de disacarina, ácido difumárico, ácido d1-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(demitilamino)butilo | |
| CO6501183A2 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| EA201170921A1 (ru) | Фармацевтическая композиция | |
| PE20141421A1 (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| PE20140038A1 (es) | Compuestos antivirales | |
| UA108640C2 (uk) | Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a | |
| GT201300309A (es) | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos | |
| PE20142185A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| PE20161363A1 (es) | Moduladores del receptor acoplado a la proteina g40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| PE20091032A1 (es) | Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |